These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17851645)

  • 1. [Anticoagulation for stroke prevention. An update].
    Koennecke HC
    Nervenarzt; 2007 Oct; 78(10):1124-9. PubMed ID: 17851645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Patient with antithrombotic medication. Which do bleedings or preoperative?].
    Stiefelhagen P
    Laryngorhinootologie; 2006 Jan; 85(1):50-60; quiz 61-5. PubMed ID: 16444657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulation in vulnerable elderly patients with atrial fibrillation : risks and benefits].
    Coutaz M
    Rev Med Suisse; 2020 Sep; 16(706):1718-1720. PubMed ID: 32936558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How should anticoagulants be used in recurrent, ischemic and hemorrhagic brain infarctions?].
    Leschke M; Klimek W
    Dtsch Med Wochenschr; 2003 Oct; 128(42):2213-4. PubMed ID: 14562222
    [No Abstract]   [Full Text] [Related]  

  • 7. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke prevention in atrial fibrillation: current status and near-future directions.
    De Caterina R; Hylek EM
    Am J Med; 2011 Sep; 124(9):793-9. PubMed ID: 21745652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Limitations of anticoagulant therapy].
    Martí-Fàbregas J; Delgado-Mederos R; Mateo J
    Neurologia; 2012 Mar; 27 Suppl 1():27-32. PubMed ID: 22682207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic treatment of atrial fibrillation: new insights.
    Le Heuzey JY
    Thromb Res; 2012 Oct; 130 Suppl 1():S59-60. PubMed ID: 23026665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticoagulation in atrial fibrillation. Strategies in special situations].
    Volkmann H; Walter M; Walter C; Vetter S
    Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice.
    Bajorek B; Magin PJ; Hilmer S; Krass I
    J Clin Pharm Ther; 2016 Aug; 41(4):432-40. PubMed ID: 27338004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
    Riva N; Lip GY
    Pol Arch Med Wewn; 2012; 122(1-2):45-53. PubMed ID: 22353706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.
    Myat A; Ahmad Y; Haldar S; Tantry US; Redwood SR; Gurbel PA; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):1029-49. PubMed ID: 23984927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    Lopes RD; Li L; Granger CB; Wang TY; Foody JM; Funk M; Peterson ED; Alexander KP
    Am J Med; 2012 Sep; 125(9):897-905. PubMed ID: 22795814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation: stroke prevention in older adults.
    Quinn GR; Fang MC
    Clin Geriatr Med; 2012 Nov; 28(4):617-34. PubMed ID: 23101573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation.
    Anderson DR; Gardner MJ; Putnam W; Jassal D; Brownell B; Flowerdew G; Nagpal S; Thompson K; Cox JL
    Can J Cardiol; 2005 Mar; 21(3):257-66. PubMed ID: 15776115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.